Investing in the athlete approach to animal nutrition.
Microbiome science for tomorrow's food supply.
Investor Relations - Important Information
The information in this Investor Relations section is provided for informational purposes only and does not constitute an offer to sell or an invitation to purchase any shares, securities, or other interests in Bebiotica N.V. This information is intended for investors who are capable of evaluating and accepting the potential risks associated with investing in our company.
The shares of Bebiotica N.V. are listed on Euronext ACCESS™ Paris. Euronext ACCESS™ is not a regulated market under EU securities regulations. The disclosure requirements and investor protection standards are less stringent than those applicable to regulated markets. This market segment is primarily designed for professional and qualified investors who can assess and accept the risks inherent in less regulated trading environments. Liquidity may be limited compared to securities traded on regulated markets. Investors should conduct their own due diligence and seek independent financial advice before making any investment decisions
Disclaimer: While we strive to ensure the accuracy of information presented on this website, Bebiotica N.V. accepts no liability for any errors, omissions, or investment decisions made based on this information.
Company portraitBebiotica N.V. – Pioneering Biomimetic Nutrition for Animal Performance
Bebiotica N.V. is a Dutch biotechnology company revolutionizing animal nutrition through biomimetic zinc technology. Founded on more than 15 years of advanced research in zinc biochemistry, we've developed a platform that harnesses nature's own defense mechanisms to strengthen animal health, improve performance, and eliminate the need for antibiotics in food production.
Treating Animals Like Athletes
Our philosophy is simple yet transformative: modern production animals face demands comparable to elite athletes. Stress from intensive farming; weaning, transport and high-density environments trigger massive zinc depletion that undermines immunity, gut integrity, and stress resilience. Traditional approaches attempt to overwhelm this problem with high-dose supplementation, causing environmental harm. Our biomimetic ZincSmart™ technology instead optimizes zinc utilization at the cellular level, maintaining functional zinc status during critical periods while using approximately 85% less zinc than conventional methods.
Breakthrough Technology
ZincSmart™ represents a fundamental shift in animal nutrition. By activating zinc's natural biological intelligence; its ability to modulate microbiomes, strengthen intestinal barriers, and enhance immune function, our technology works with the animal's own physiology rather than suppressing pathogens with chemicals. Independent validation demonstrated remarkable results: 30% mortality reduction in pigs, 8-12% feed conversion improvement, enhanced meat quality, and significantly better intestinal health markers.
Addressing Critical Market Needs
We target four high-growth sectors facing urgent antimicrobial resistance and animal health challenges: beekeeping (€800M+ global market), pig production (€2.5B EU market), poultry farming (€12B global market), and salmon aquaculture (€8B market). These industries share common needs; antibiotic-free production, improved gut health, regulatory compliance, but have lacked scientifically validated natural solutions. With proven efficacy, ready-to-market products, and strategic manufacturing partnerships, Bebiotica is positioned to capture meaningful market share across multiple species platforms.
Strong Business Economics
Our asset-light business model delivers exceptional financial characteristics: 60-70% gross margins, outsourced manufacturing to certified EU partners, rapid scalability, and recurring revenue from continuous feed additive consumption. The platform technology applies across multiple species, amortizing R&D investment while creating diversified revenue streams and reducing concentration risk.
Market Timing and Regulatory Advantage
Global regulatory trends create powerful tailwinds. The EU's complete antibiotic ban (2022), restrictions on high-dose zinc oxide (2023), China's mandatory antibiotic reduction, and growing retailer demands for antibiotic-free production don't just encourage adoption, they mandate solutions. Bebiotica addresses legally-required problems, not optional improvements.
Path to Value
Bebiotica combines breakthrough science with massive market potential. We represent a compelling opportunity at the intersection of biotechnology, sustainable agriculture, and regulatory transformation, with a clear path to profitability and strong strategic partnership appeal from the industry actively seeking antibiotic alternatives.
Managementboard
Mr. Michael van der Jagt
Mr. Michele FioriDate of incorporation:
4 September 2012End of fiscal year
31 December
Issued Capital
€ 104,227,60Exchange
Euronext Access™Ticker
MLPRXISIN
NL0012650535Total number of shares
xx,xxxx,xxxLatest news
Any questions?
Just reach out….